Search clinical trials for: AZD3759

Total 43 results

LYZZ Alpha Holding Ltd
Tigermed Consulting Co., Ltd

Completed

Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759

Non Small Cell Lung Cancer

China
AstraZeneca

Completed

A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers

Asthma, Chronic Obstructive Pulmonary Disease (COPD)

Germany
AstraZeneca

Completed

Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers

Healthy Volunteers | Alzheimer's Disease | Tolerability | Safety | Blood Concentration

United Kingdom
AstraZeneca
Parexel

Completed

A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

Germany
AstraZeneca

Recruiting

Study of AZD0754 in Participants With Metastatic Prostate Cancer (APOLLO)

Metastatic Prostate Cancer

United States, Australia
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

Asthma | Chronic Obstructive Pulmonary Disease COPD

United States
AstraZeneca

Active, not recruiting

Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study

COVID-19

United States
AstraZeneca

Active, not recruiting

Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult Participants

COVID-19, SARS-CoV-2

Japan
AstraZeneca
Parexel

Completed

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

Asthma

United States, Germany, South Africa, Ukraine, Japan, Hungary, Poland, Bulgaria
AstraZeneca

Not yet recruiting

LTFU for All Cell and Gene Therapy Studies (LOCUS)

Hepatocellular Carcinoma | Prostate Cancer

United States
AstraZeneca
Parexel

Recruiting

Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Relapsed or Refractory Classical Hodgkin Lymphoma

Italy, United States, Spain, United Kingdom, Canada, Denmark, France, China, Germany
AstraZeneca

Recruiting

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

Carcinoma, Non-Small-Cell Lung | Gastric Cancer | Gastroesophageal Junction Cancer

United States, Canada, Spain, China, Japan, France, Turkey, Netherlands, Moldova, Republic of, Georgia
AstraZeneca
Parexel

Completed

A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects.

Asthma

Germany
AstraZeneca

Active, not recruiting

Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19 (NOVELLA)

COVID-19, SARS-CoV-2

Russian Federation
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594

Pharmacokinetics | Safety | Pharmacodynamics of AZD7594

United Kingdom
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma

Asthma

United States
AstraZeneca

Completed

A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

United States
AstraZeneca

Completed

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer (BLOOM)

EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Australia
AstraZeneca

Completed

A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma

Asthma | Efficacy | Safety

Germany, Bulgaria
Alpha Biopharma (Jiangsu) Co., Ltd.

Completed

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases (BM)

Non-small Cell Lung Cancer | Brain Metastases | EGFR Gene Mutation

China, Korea, Republic of, Singapore, Taiwan
National Taiwan University Hospital
Ministry of Science and Technology, Taiwan

Unknown

Lesogaberan in Chinese Patients With Refractory Reflux Symptoms

Gastroesophageal Reflux Disease

Taiwan
AstraZeneca

Completed

Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma

Asthma

Sweden
AstraZeneca

Active, not recruiting

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (SUPERNOVA)

COVID-19, SARS-CoV-2

United States, Belgium, Canada, France, Spain, Denmark, Thailand, Vietnam, Korea, Republic of, United Kingdom, Malaysia, Israel, Taiwan, Australia, Germany, Poland, Singapore, United Arab Emirates
AstraZeneca
Daiichi Sankyo

Recruiting

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04)

Advanced or Metastatic NSCLC

United States, Taiwan, Italy, Spain, Poland, Japan, Belgium, Turkey, France, Korea, Republic of
Presage Biosciences
Merck Sharp & Dohme LLC

Recruiting

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Solid Tumor

United States
AstraZeneca

Completed

Study to Compare Different Formulations of AZD3355

Gastroesophageal Reflux Disease

Sweden
AstraZeneca

Completed

TLESR-impedance Study in Patients

Reflux Episodes
AstraZeneca

Completed

Renal Impairment Study

Reflux | Renal Excretion

Sweden
AstraZeneca

Completed

AZD3355 Dose-escalation Study in Healthy Males

Reflux Disease

Sweden
AstraZeneca

Completed

Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients

Gastroesophageal Reflux Disease (GERD)

Hungary, Romania, Norway, Belgium, France, Netherlands, Germany, Australia
AstraZeneca

Completed

Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms (C27)

GERD | Heartburn | Acid Reflux Disease | Regurgitation

United States
AstraZeneca

Completed

Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI

Gastroesophageal Reflux Disease | Heartburn | Regurgitation

United States
AstraZeneca

Completed

A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience

Gastroesophageal Reflux Disease

United States
Presage Biosciences
AstraZeneca

Not yet recruiting

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC

Head and Neck Squamous Cell Carcinoma

United States
AstraZeneca

Completed

Multiple Ascending Doses (MAD) of AZD3199 Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men (AZD3199MAD)

Healthy Volunteers

Sweden
AstraZeneca

Recruiting

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

Spain, China, Korea, Republic of, United States, Taiwan, Japan, United Kingdom
AstraZeneca

Completed

Assess Safety, Tolerability and PK of AZD3199 in Japanese

Healthy

United Kingdom
AstraZeneca

Completed

Drug Interaction Study Between AZD3355 and Nexium

Gastroesophageal Reflux Disease

Sweden
Takeda

Terminated

A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers

Duodenal Ulcer | Stomach Ulcer

Japan
AstraZeneca

Completed

Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients (GLAD)

COPD

Bulgaria, Poland, Russian Federation, Japan, Canada
Guangdong Association of Clinical Trials
Chinese Thoracic Oncology Group

Recruiting

Phase II Umbrella Study Directed by Next Generation Sequencing (TRUMP)

Carcinoma, Non-Small-Cell Lung

China
AstraZeneca

Completed

Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199

Asthma | Airway Obstruction

Sweden, Denmark
AstraZeneca

Completed

To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart

Chronic Obstructive Pulmonary Disease | Lung Disease

United Kingdom

3

Subscribe